Divest, Refocus, Transition: Multinationals Embark On Uncharted Path In China
Executive Summary
Facing unprecedented pricing pressures in China, multinationals are embarking on a major shift away from mature products to focus more on innovative drugs, but there are major challenges linked to the transition that won’t be easy to navigate, notes a new report.
You may also be interested in...
China Pharma Sales Bring Bayer Relief From Monsanto Legal Woes
Xarelto and Eylea are continuing to sell well but the German major faces another heap of litigation in the US over Monsanto's weedkillers which is alarming shareholders.
Asia Deal Watch: Shionogi Finds Commercial Partners For Symproic In US, Europe
Shionogi licenses US commercial rights for OIC drug to BioDelivery and rights in three EU markets to Sandoz. Tessa will test its T-cell therapy with Merck’s Keytruda in cervical cancer.
Drug Price Waterloo: China's New Bidding Process Hits MNCs Hard
China's new so-called “4+7” drug bidding pilot scheme, already expected to be a killer for some companies, has cut prices by as much as 90%, leaving all but two multinationals to bid successfully and accept the revised levels. The big reductions could also lead to further price erosion for the winning products.
Need a specific report? 1000+ reports available
Buy Reports